A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

• Status: Recruiting
• Trial end date: 2022-12-22
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage III non-small cell lung cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shandong Cancer Hospital and Institute

Criteria

Inclusion Criteria:

• 1. The patients volunteered to participate in this study and signed the informed consent;

• 2. Pathologically confirmed as a newly diagnosed and unresectable locally advanced non-small cell lung cancer (STAGE IIIA/ IIIB) with measurable lesions;IIIa3: Multistation lymph node metastases detected by mediastinoscopy, other lymph node biopsy, or PET/CT;IIIa4: Massive or fixed multistation N2 lymph node metastasis (massive lymph nodes, defined as lymph nodes with a short diameter of more than 2 cm on a helical CT scan, especially those with extranode invasion).;Patients with IIIb.In addition, T3/4 with multiple satellite nodules in the ipsilateral or contralateral lung was not included in this study.

• 3. Patients with negative EGFR, ALK and ROS1 gene test results;

• 4. Ages 18-75, regardless of gender;

• 5. ECOG score: 0-1;

• 6. Expected survival over 3 months;

• 7. Function of major organs within 7 days prior to treatment meets the following criteria:

A. Standard of blood routine examination (without blood transfusion within 14 days) :

I. Hemoglobin (HB) ≥100 g/L; II. WBC ≥3.0×109/L; Iii. Platelet (PLT) ≥100×109/L.

B. Biochemical examination shall meet the following standards:

I. Total bilirubin (TBIL) ≤1.5 times the upper limit of normal value (ULN); II. AST≤2.5×ULN of alanine aminotransferase (ALT) and aspartate aminotransferase (ASpartate), if accompanied by liver metastasis, ALT and AST≤5×ULN; III. Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance rate (CCr)≥60ml/min; C. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ lower normal limit (50%); D. Pulmonary function assessment: FEV1≥1.45 l/s.

• 8. Patients of childbearing age (including female and female partners of male patients) must take effective birth control measures

Exclusion Criteria:

• 1. Patients who have previously used anlotinib hydrochloride capsules;

• 2. Small cell lung cancer (including mixed small cell and non-small cell cancers);

• 3. Lung squamous cell carcinoma with empty cavity, or non-small cell lung cancer with hemoptysis (> 20ml/day);

• 4. Patients with other malignant tumors other than NSCLC within 5 years before the start of treatment in this study (except those with simple surgical resection and disease-free survival for at least 5 consecutive years, cured cervical carcinoma in situ, cured basal cell carcinoma and bladder epithelial tumor);

• 5. Systemic antitumor therapy, including cytotoxic therapy, signal transduction inhibitors and immunotherapy, is planned within 4 weeks before enrollment or during the medication period of this study.In addition to thymosin, lentinan and other immunomodulator treatment.

• 6. Unmitigated toxicity due to any previous treatment above CTC AE level 1, excluding hair loss;

• 7. Patients with multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);

• 8. Accompanied by pleural effusion or ascites, causing respiratory syndrome (≥CTC AE level 2 dyspnea);

• 9. Patients with any severe and/or uncontrolled disease, including: A) Patients with unsatisfactory blood pressure control (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100 mmHg); B) Having grade I or above myocardial ischemia or infarction, arrhythmia (including QTc ≥480ms), and grade 2 or above congestive heart failure (New York Heart Association (NYHA) classification); C) Active or uncontrolled severe infection (≥CTC AE level 2 infection); D) Antiviral treatment for cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis; E) Renal failure requires hemodialysis or peritoneal dialysis; F) A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; G) poor control of diabetes mellitus (FBG) > 10mmol/L; H) urine routine indicated urinary protein ≥++, and confirmed 24-hour quantitative urinary protein > 1.0g; I) patients with epileptic seizures requiring treatment; J) Patients with gastric ulcer

• 10. Receive major surgical treatment, open biopsy or significant traumatic injury within 28 days before grouping;

• 11. Patients whose tumors have invaded important blood vessels according to imaging findings or whose tumors are likely to invade important blood vessels during the follow-up study according to the judgment of the researchers, resulting in fatal massive hemorrhage;

• 12. Patients with any physical signs or history of bleeding, regardless of severity;Patients with any bleeding or bleeding event ≥CTCAE level 3 within 4 weeks prior to enrollment have unhealed wounds, ulcers or fractures;

• 13. Occurrence of ARTERIAL/venous thrombotic events, such as cerebrovascular accidents (including temporary ischemic attacks), deep venous thrombosis and pulmonary embolism within 6 months;

• 14. Persons with a history of abuse of psychotropic substances and who cannot be cured or have mental disorders;

• 15. Pregnant and lactating women;

• 16. Participated in other clinical trials of anti-tumor drugs within 4 weeks;

• 17. The researcher considered that there were other conditions that were not suitable for inclusion.